Please assess the completion status of the following clinical trial:

Trial Title: A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Participants (Part 1 only)~  * Males 18 to 45 to years of age~ * Baseline left ventricular ejection fraction (LVEF) greater than (\>) 60 percent (%)~* HER2-Positive Females (Parts 1 and 2)~  * Females greater than or equal to (≥) 18 years of age~ * Eastern Cooperative Oncology Group (ECOG) performance status of 0~ * Previous non-metastatic operable primary invasive HER2-positive breast cancer~ * Baseline LVEF \>55%~Exclusion Criteria:~* Healthy Participants (Part 1 only)~  * Clinically significant abnormalities in laboratory test results or electrocardiogram~ * History of significant allergies, gastrointestinal, renal, hepatic, cardiovascular, or pulmonary disease~ * History of hypersensitivity or allergic reaction, spontaneous or following drug administration~ * History of cardiac conditions~* HER2-Positive Females (Parts 1 and 2)~  * Metastatic disease~ * Concurrent other malignancy requiring therapy of any modality which may interfere with PK investigations or result in unexpected toxicity~ * Use of Herceptin in previous 5 months~ * Serious cardiac illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Part 1: Cohort 1 (Type: EXPERIMENTAL): Healthy male participants will receive Herceptin 6 mg/kg IV on Day 1.
- Part 1: Cohort 2 (Type: EXPERIMENTAL): Female participants with HER2-positive breast cancer will receive Herceptin 6 mg/kg IV on Day 1.
- Part 1: Cohort 3 (Type: EXPERIMENTAL): Healthy male participants will receive Herceptin 6 mg/kg SC on Day 1.
- Part 1: Cohort 4 (Type: EXPERIMENTAL): Healthy male participants will receive Herceptin 10 mg/kg SC on Day 1.
- Part 1: Cohort 5 (Type: EXPERIMENTAL): Healthy male participants will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohorts 1, 2, 3, and 4.
- Part 2: Cohort A (Type: EXPERIMENTAL): Female participants with HER2-positive breast cancer will receive Herceptin SC at the dose level determined in Part 1.
- Part 2: Cohort B (Type: EXPERIMENTAL): Female participants with HER2-positive breast cancer will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohort A.

Based on this trial design, predict the completion outcome and termination type (if applicable).